Rigel Pharmaceuticals (RIGL)
(Real Time Quote from BATS)
$0.95 USD
-0.03 (-3.28%)
Updated May 14, 2024 03:04 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Income Statements
Fiscal Year end for Rigel Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 117 | 120 | 149 | 109 | 59 |
Cost Of Goods | 7 | 2 | 1 | 1 | 1 |
Gross Profit | 110 | 118 | 148 | 108 | 58 |
Selling & Adminstrative & Depr. & Amort Expenses | 130 | 174 | 161 | 137 | 127 |
Income After Depreciation & Amortization | -20 | -56 | -13 | -29 | -69 |
Non-Operating Income | 2 | 1 | 0 | 1 | 3 |
Interest Expense | 7 | 4 | 5 | 1 | 0 |
Pretax Income | -25 | -59 | -17 | -30 | -67 |
Income Taxes | 0 | 0 | 1 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -25 | -59 | -18 | -30 | -67 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -25 | -59 | -18 | -30 | -67 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -20 | -55 | -11 | -28 | -69 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | 0 |
Income After Depreciation & Amortization | -20 | -56 | -13 | -29 | -69 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 173.90 | 172.41 | 170.49 | 168.75 | 167.40 |
Diluted EPS Before Non-Recurring Items | -0.14 | -0.34 | -0.11 | -0.18 | -0.40 |
Diluted Net EPS (GAAP) | -0.14 | -0.34 | -0.11 | -0.18 | -0.40 |
Fiscal Year end for Rigel Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 29.53 | 35.79 | 28.13 | 26.89 | 26.07 |
Cost Of Goods | 2.03 | 3.79 | 1.27 | 1.08 | 0.98 |
Gross Profit | 27.51 | 32.00 | 26.87 | 25.81 | 25.09 |
SG&A, R&D, and Dept/Amort Expenses | 34.48 | 30.04 | 31.34 | 31.08 | 37.82 |
Income After SG&A, R&D, and Dept/Amort Expenses | -6.97 | 1.96 | -4.47 | -5.27 | -12.73 |
Non-Operating Income | 0.59 | 0.68 | 0.67 | 0.53 | 0.39 |
Interest Expense | 1.87 | 1.91 | 1.90 | 1.86 | 1.20 |
Pretax Income | -8.25 | 0.74 | -5.69 | -6.60 | -13.54 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -8.25 | 0.74 | -5.69 | -6.60 | -13.54 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -8.25 | 0.74 | -5.69 | -6.60 | -13.54 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 175.20 | 174.47 | 174.36 | 173.75 | 173.57 |
Diluted EPS Before Non-Recurring Items | -0.05 | 0.00 | -0.03 | -0.04 | -0.08 |
Diluted Net EPS (GAAP) | -0.05 | 0.01 | -0.03 | -0.04 | -0.08 |